文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

急性呼吸衰竭亚表型的床旁识别(PHIND):一项多中心观察性队列研究

Bedside identification of subphenotypes in acute respiratory failure (PHIND): a multicentre, observational cohort study.
PubMed 文献 · Lancet Respir Med · 2026-03-23
一句话结论在成人ARDS或急性低氧性呼吸衰竭患者中,用床旁免疫分析仪约1小时测定血浆IL-6、TNFR1和碳酸氢盐可前瞻性分型,高炎症型60天死亡率51%高于低炎症型28%。

PHIND为前瞻性多中心观察性队列研究,在英、爱ICU纳入成人ARDS或急性低氧性呼吸衰竭患者,于综合征起病72小时内入组,采用床旁免疫分析仪测定血浆IL-6、可溶性TNF受体-1及动脉血碳酸氢盐,用已验证的简约逻辑回归模型前瞻性判定亚表型。512例纳入分析,490例完成床旁分型:高炎症型89例(18%),低炎症型401例(82%)。高炎症型60天死亡率51%(45/88)高于低炎症型28%(111/398),风险比1.8(95%CI 1.4-2.4),p<0.0001;校正后高炎症型60天死亡比值比2.7(95%CI 1.6-4.4),p=0.0002。作者认为床旁快速识别ARDS炎症亚表型可行,支持在ARDS中实施精准医学方法并亟需前瞻性、按亚表型分层的干预试验。

要点

  • 成人ARDS或急性低氧性呼吸衰竭患者起病72小时内、接受有创机械通气、无创通气或高流量鼻氧时可入组。
  • 床旁免疫分析仪(Randox multiSTAT)约1小时出结果,联合血浆IL-6、可溶性TNF受体-1和动脉血碳酸氢盐前瞻性判定亚表型。
  • 490例可分型患者中高炎症型89例(18%)、低炎症型401例(82%)。
  • 高炎症型60天死亡率51%(45/88)高于低炎症型28%(111/398),风险比1.8(95%CI 1.4-2.4),p<0.0001。
  • 校正后高炎症型60天死亡比值比2.7(95%CI 1.6-4.4),p=0.0002。

适用人群与场景

  • 英国国家卫生服务体系与爱尔兰健康服务管理署ICU内18岁及以上成人ARDS或急性低氧性呼吸衰竭患者,于综合征起病72小时内入组。
  • 入组时需接受有创机械通气、无创通气或高流量鼻氧。

诊断标准与关键阈值

  • 采用已验证的简约逻辑回归模型,基于血浆IL-6、可溶性TNF受体-1和动脉血碳酸氢盐前瞻性判定高炎症型与低炎症型亚表型。

研究设计与关键结果

  • 前瞻性、多中心、观察性队列研究,2019年11月22日至2023年9月28日筛查1853例,排除1328例,招募525例,最终纳入512例分析。
  • 308例(60%)男性,204例(40%)女性,平均年龄57.0岁(SD 15.1);443例(87%)白人,18例(4%)黑人,16例(3%)亚裔。
  • 490例用床旁分析仪完成分型:高炎症型89例(18%),低炎症型401例(82%)。
  • 60天死亡率在486例中测定(4例撤回生命状态确认同意):高炎症型45/88(51%) vs 低炎症型111/398(28%),风险比1.8(95%CI 1.4-2.4),p<0.0001。
  • 校正后高炎症型60天死亡比值比2.7(95%CI 1.6-4.4),p=0.0002。

证据类型、等级与局限

  • 证据类型:前瞻性、多中心、观察性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为床旁快速识别ARDS炎症亚表型可行,结果与既往回顾性研究在死亡率、脓毒症患病率和代谢性酸中毒发生率等方面一致。
  • 作者认为这些发现支持在ARDS中实施精准医学方法,并亟需前瞻性、按亚表型分层的干预试验。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Acute respiratory distress syndrome (ARDS) is a clinically defined, biologically heterogeneous condition with no proven disease-modifying therapies. Retrospective analyses have identified two biologically distinct subphenotypes (hyperinflammatory and hypoinflammatory) of ARDS, with differing outcomes and responses to therapy. Rapid identification of these subphenotypes in an actionable timeframe has previously not been possible. The PHIND study aimed to prospectively identify these subphenotypes and to demonstrate differing 60-day mortality.

METHODS: The PHIND study was a prospective, multicentre, observational cohort study conducted in intensive care units (ICUs) within the National Health Service in the UK and the Health Service Executive in Ireland. Adult patients aged 18 years and older with ARDS or acute hypoxaemic respiratory failure (AHRF) were enrolled within 72 h of onset of the syndrome. Eligible patients were required to be receiving invasive mechanical ventilation, non-invasive ventilation, or high-flow nasal oxygen. Plasma interleukin (IL-6) and soluble TNF receptor-1 (TNFR1) were quantified at enrolment using a near-patient benchtop immunoanalyser (Randox multiSTAT) with a run time of approximately 1 h. Together with plasma bicarbonate measured from an arterial blood sample, these values were used to prospectively determine subphenotypes on an individual patient basis using a validated parsimonious logistic regression model. The primary outcome was 60-day mortality. The study was registered on ClinicalTrials.gov, NCT04009330.

FINDINGS: Between Nov 22, 2019, and Sept 28, 2023, 1853 patients from 30 centres were screened for eligibility. Of these, 1328 were excluded and 525 were recruited into the study, with 512 individuals included. 308 (60%) patients were male, 204 (40%) were female, and mean age was 57·0 years (SD 15·1). 443 (87%) patients were white, 18 (4%) were Black, and 16 (3%) were Asian. 490 were subphenotyped using the near-patient assay: 89 (18%) were classified as hyperinflammatory and 401 (82%) as hypoinflammatory. The primary outcome of 60-day mortality was measured in 486 patients after four patients withdrew consent for confirmation of vital status. 60-day mortality was significantly higher in the hyperinflammatory group (45 [51%] of 88) than in the hypoinflammatory group (111 [28%] of 398; risk ratio 1·8 [95% CI 1·4-2·4], p<0·0001). After adjustment, hyperinflammatory patients had increased odds of 60-day mortality (adjusted odds ratio 2·7 [95% CI 1·6-4·4], p=0·0002).

INTERPRETATION: Rapid identification of ARDS inflammatory subphenotypes using a near-patient assay was feasible and associated with many clinical characteristics and outcomes consistent with those described in earlier retrospective studies, including mortality, prevalence of sepsis, and incidence of metabolic acidosis. These findings support the implementation of precision medicine approaches in ARDS and the urgent need for prospective, subphenotype-stratified interventional trials.

FUNDING: Innovate UK, Randox Laboratories, and Belfast Health & Social Care Trust.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

参考来源

  1. Reddy K, Sinha P, Antcliffe DB, et al. Bedside identification of subphenotypes in acute respiratory failure (PHIND): a multicentre, observational cohort study. Lancet Respir Med. 2026. PMID: 41887245. doi:10.1016/S2213-2600(26)00040-8

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。